Hennion & Walsh Asset Management, Inc. Myovant Sciences Ltd. Transaction History

Hennion & Walsh Asset Management, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 12, 2023	SELL	$24.03 - $27.02 $3.4 Million - $3.82 Million	-141,504 Reduced 52.82%	126,398 $3.41 Million
Q3 2022 Nov 14, 2022	SELL	$11.6 - $20.44 $132,622 - $233,690	-11,433 Reduced 4.09%	267,902 $4.81 Million
Q2 2022 Jul 19, 2022	SELL	$7.78 - $14.69 $1.01 Million - $1.91 Million	-129,744 Reduced 31.72%	279,335 $3.47 Million
Q1 2022 Apr 26, 2022	SELL	$11.38 - $16.4 $287,857 - $414,837	-25,295 Reduced 5.82%	409,079 $5.45 Million
Q4 2021 Feb 14, 2022	BUY	$14.31 - $23.87 $131,251 - $218,935	9,172 Added 2.16%	434,374 $6.76 Million
Q3 2021 Nov 12, 2021	BUY	$18.94 - $26.99 $93,222 - $132,844	4,922 Added 1.17%	425,202 $9.54 Million
Q2 2021 Aug 13, 2021	BUY	$17.07 - $24.56 $357,616 - $514,532	20,950 Added 5.25%	420,280 $9.57 Million
Q1 2021 May 17, 2021	BUY	$20.46 - $25.18 $8.17 Million - $10.1 Million	399,330 New	399,330 $8.22 Million

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.